CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq: CUVL) reported its tenth consecutive annual profit for FY2026, with net profit after tax of $33.9 million (down 6% year-on-year) and revenues from ordinary activities of $94.0 million (down 1%), while total revenue plus other income reached $101.2 million.
Expenses edged down to $53.5 million, supporting a net profit before tax of $47.7 million, affected by unrealised foreign currency losses on US dollar term deposits. Cash reserves rose 12% to $252.1 million, net tangible assets per share increased to $5.35, and operating cash inflow was $36.9 million, enabling self-financed U.S. expansion.
The Board declared a fully franked $0.05 dividend per share for the ninth consecutive annual dividend, representing about 9% of FY2026 free cash generated, with ex-dividend on 3 September 2026 and payment on 18 September 2026.
CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq: CUVL) announced a strategic reorganisation, effective 1 January 2027, including relocating its corporate headquarters and key functions from Australia to the United States. The move aims to strengthen U.S. regulatory engagement, commercial partnerships, and access to deeper capital markets.
The company will reduce its global workforce by approximately 10%-20% and relocate selected functions to the U.S., aligning operating expenditure with current revenue and near-term clinical and commercial priorities. Operational resources will be focused exclusively on the U.S. pharmaceutical pipeline, notably late-stage programs in vitiligo, targeting an estimated six million U.S. patients.
According to CLINUVEL, over 66% of its shareholder register is foreign, with many investors in North America and Europe. Management cites higher valuation multiples for comparable U.S.-listed specialty pharma peers and the dominance of the U.S. in global pharmaceutical market value as key drivers of the strategic shift.
CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq planned: CUVL) announced that its American Depositary Share is expected to begin trading later today (New York time) on the Nasdaq Global Select Market under ticker CUVL, after the SEC declared its Form 20-F registration effective on 17 July and Nasdaq approved the listing.
The company’s over-the-counter ADR (CLVLY) will be upgraded from Level I to Level II, with each CUVL ADS representing one ordinary ASX-listed share. CLINUVEL does not plan to raise capital or issue new shares for this upgrade, and existing CLVLY holders need not take action. The company cautions that no final decision on the uplisting has been made and there is no guarantee trading will commence as expected.